Human Interleukin 8
Also known as: CXCL8, GCP-1, GRO‑α, IL-8, IL‑8, Monocyte-derived neutrophil chemotactic factor, NAP-1, NAP‑1, Neutrophil-activating protein 1
Source Human Interleukin 8 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Human Interleukin‑8 (IL‑8, CXCL8) is a 72‑amino‑acid chemokine that mediates neutrophil recruitment and activation during acute inflammation. It is used experimentally as a biomarker and as a research tool; no approved therapeutic formulations exist.
Mechanism of Action
Binds CXCR1 and CXCR2 receptors on neutrophils, triggering intracellular signaling that drives chemotaxis, degranulation, and activation of inflammatory responses.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
- Biomarker for infection/inflammationDiagnosticHigh
- Research biomarker for inflammationBiomarker / DiagnosticsHigh
- Therapeutic target in oncologyAnti CancerModerate
- Modulate neutrophil chemotaxisAnti‑inflammatoryModerate
- Wound healing / angiogenesis researchTissue RepairLow
- Therapeutic target for inflammatory diseasesAnti InflammatoryModerate
Contraindications
- Not applicable as therapeutic agentGeneralHigh
Adverse Effects
- Pro-inflammatory cytokine storm contributionImmunologicalUnknown
- Neutrophil-mediated tissue damageImmunologicalUnknown
- Promotion of tumor angiogenesisOncologicalUnknown
Drug Interactions
- Anti-IL-8 monoclonal antibodies (e.g., BMS-986253)Low
- CXCR1/CXCR2 antagonists (e.g., reparixin, navarixin)Low
Population Constraints
- Not for therapeutic use in any populationGeneral PopulationAbsolute
Regulatory Status
- European UnionUnapprovedNot approved by EMA as a therapeutic. Research and investigational use only.
- United StatesUnapprovedNot approved by FDA as a therapeutic. Used as a research reagent and biomarker. Anti-IL-8 therapies are in investigational trials.
- United KingdomUnapprovedNot approved by MHRA as a therapeutic. Research and biomarker use only.
IL-8 (CXCL8) is not approved as a therapeutic agent in any jurisdiction. It is used as a biomarker and research tool. Anti-IL-8 antibodies (e.g., BMS-986253/HuMax-IL8) and CXCR1/CXCR2 antagonists targeting this pathway are in clinical trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Human Interleukin 8?
Human Interleukin‑8 (IL‑8, CXCL8) is a 72‑amino‑acid chemokine that mediates neutrophil recruitment and activation during acute inflammation. It is used experimentally as a biomarker and as a research tool; no approved therapeutic formulations exist.
What is Human Interleukin 8 used for?
Human Interleukin 8 is educationally associated with: Biomarker for infection/inflammation, Research biomarker for inflammation, Therapeutic target in oncology, Modulate neutrophil chemotaxis, Wound healing / angiogenesis research, Therapeutic target for inflammatory diseases. Educational only — not medical advice.
What are the potential side effects of Human Interleukin 8?
Reported adverse effects include: Pro-inflammatory cytokine storm contribution, Neutrophil-mediated tissue damage, Promotion of tumor angiogenesis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Human Interleukin 8?
Recorded contraindications: Not applicable as therapeutic agent. Consult a qualified clinician before use.